FOXP1在卵巢癌中的作用及其机制
The Role and Mechanism of FOXP1 in Ovarian Cancer
DOI: 10.12677/ACM.2021.116380, PDF,    国家自然科学基金支持
作者: 陈 阳：昆明理工大学附属医院/云南省第一人民医院，云南 昆明；转 黎, 李云秀, 胥 琴*：云南省第一人民医院生殖医学科，云南 昆明
关键词: Forkhead Box P1；卵巢癌；治疗靶点；Forkhead Box P1； Ovarian Cancer； Therapeutic Targets
摘要: 卵巢癌缺少早期诊断方法，而晚期患者通过肿瘤细胞减灭术和基础化疗等传统治疗方案后易复发，因此从卵巢癌发生发展的分子机制探索新的分子标志物和治疗靶点意义重大。Forkhead Box P1 (FOXP1)作为转录因子密切参与卵巢癌的发生发展进程，近些年的研究表明，高表达的FOXP1通过促进上皮–间充质转化、调节肿瘤干细胞特性、调控多种分子信号转导通路等机制影响卵巢癌细胞增殖、转移、侵袭和化疗抗性。本文通过简要论述转录因子FOXP1在卵巢癌中的作用及其机制研究的最新进展，旨在为卵巢癌早期诊断和临床治疗寻找新的分子靶标。
Abstract: There is a lack of early diagnosis of ovarian cancer, and advanced patients are prone to relapse after traditional treatment such as cytoreductive surgery and basic chemotherapy. Therefore, it is of great significance to explore new molecular markers and therapeutic targets from the molecular mechanism of ovarian cancer development. As a transcription factor, Forkhead Box P1 (FOXP1) is closely involved in the occurrence and development of ovarian cancer. Recent studies have shown that high expression of FOXP1 affects the proliferation, metastasis, invasion and chemotherapy resistance of ovarian cancer cells by promoting epithelial mesenchymal transition, regulating the characteristics of tumor stem cells, and regulating a variety of molecular signal transduction pathways. In this paper, we briefly discuss the role of FOXP1 in ovarian cancer and the latest progress of its mechanism, aiming to find a new molecular target for early diagnosis and clinical treatment of ovarian cancer.
文章引用：陈阳, 转黎, 李云秀, 胥琴. FOXP1在卵巢癌中的作用及其机制[J]. 临床医学进展, 2021, 11(6): 2633-2638. https://doi.org/10.12677/ACM.2021.116380

参考文献

[1] Webb, P.M. and Jordan, S.J. (2017) Epidemiology of Epithelial Ovarian Cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 41, 3-14. [Google Scholar] [CrossRef] [PubMed]
[2] Narod, S. (2016) Can Advanced-Stage Ovarian Cancer Be Cured? Nature Reviews Clinical Oncology, 13, 255-261. [Google Scholar] [CrossRef] [PubMed]
[3] Choi, E.J., Seo, E.J., Kim, D.K., Lee, S.I., Kwon, Y.W., Jang, I.H., et al. (2016) FOXP1 Functions as an Oncogene in Promoting Cancer Stem Cell-Like Characteristics in Ovarian Cancer Cells. Oncotarget, 7, 3506-3519. [Google Scholar] [CrossRef] [PubMed]
[4] Katoh, M., Igarashi, M., Fukuda, H., Nakagama, H. and Katoh, M. (2013) Cancer Genetics and Genomics of Human FOX Family Genes. Cancer Letters, 328, 198-206. [Google Scholar] [CrossRef] [PubMed]
[5] Koon, H.B., Ippolito, G.C., Banham, A.H. and Tucker, P.W. (2007) FOXP1: A Potential Therapeutic Target in Cancer. Expert Opinion on Therapeutic Targets, 11, 955-965. [Google Scholar] [CrossRef] [PubMed]
[6] Kim, J.H., Hwang, J., Jung, J.H., Lee, H.-J., Lee, D.Y. and Kim, S.-H. (2019) Molecular Networks of FOXP Family: Dual Biologic Functions, Interplay with Other Molecules and Clinical Implications in Cancer Progression. Molecular Cancer, 18, Article No. 180. [Google Scholar] [CrossRef] [PubMed]
[7] Hu, Z., Zhu, L., Gao, J., Cai, M., Tan, M., Liu, J., et al. (2015) Expression of FOXP1 in Epithelial Ovarian Cancer (EOC) and Its Correlation with Chemotherapy Resistance and Prognosis. Tumor Biology, 36, 7269-7275. [Google Scholar] [CrossRef] [PubMed]
[8] Hu, Z., Cai, M., Zhang, Y., Tao, L. and Guo, R. (2020) miR-29c-3p Inhibits Autophagy and Cisplatin Resistance in Ovarian Cancer by Regulating FOXP1/ATG14 Pathway. Cell Cycle, 19, 193-206. [Google Scholar] [CrossRef] [PubMed]
[9] Ricci, F., Fratelli, M., Guffanti, F., Porcu, L., Spriano, F., Dell’Anna, T., et al. (2017) Patient-Derived Ovarian Cancer Xenografts Re-Growing after a Cisplatinum Treatment Are Less Responsive to a Second Drug Rechallenge: A New Experimental Setting to Study Response to Therapy. Oncotarget, 8, 7741-7451. [Google Scholar] [CrossRef] [PubMed]
[10] Nameki, R., Chang, H., Reddy, J., Corona, R.I. and Lawrenson, K. (2021) Transcription Factors in Epithelial Ovarian Cancer: Histotype-Specific Drivers and Novel Therapeutic Targets. Pharmacology & Therapeutics, 220, Article ID: 107722. [Google Scholar] [CrossRef] [PubMed]
[11] Li, H., Liang, J., Qin, F. and Zhai, Y. (2018) MiR-374b-5p-FOXP1 Feedback Loop Regulates Cell Migration, Epithelial-Mesenchymal Transition and Chemosensitivity in Ovarian Cancer. Biochemical and Biophysical Research Communications, 505, 554-560. [Google Scholar] [CrossRef] [PubMed]
[12] Liao, J., Qian, F., Tchabo, N., Mhawech-Fauceglia, P., Beck, A., Qian, Z., et al. (2014) Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism. PLoS ONE, 9, e84941. [Google Scholar] [CrossRef] [PubMed]
[13] Zhu, L., Hu, Z., Liu, J. Gao, J. and Lin, B. (2015) Gene Expression Profile Analysis Identifies Metastasis and Chemoresistance-Associated Genes in Epithelial Ovarian Carcinoma Cells. Medical Oncology, 32, Article No. 426. [Google Scholar] [CrossRef] [PubMed]
[14] Roy, L. and Cowden Dahl, K.D. (2018) Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer? Cancers (Basel), 10, Article No. 241. [Google Scholar] [CrossRef] 
[15] Giatromanolaki, A., Koukourakis, M.I., Sivridis, E., Gatter, K.C., Harris, A.L. and Banham, A.H. (2006) Loss of Expression and Nuclear/Cytoplasmic Localization of the FOXP1 Forkhead Transcription Factor Are Common Events in Early Endometrial Cancer: Relationship with Estrogen Receptors and HIF-1alpha Expression. Modern Pathology, 19, 9-16. [Google Scholar] [CrossRef] [PubMed]
[16] Bates, G.J., Fox, S.B., Han, C., Launchbury, R., Leek, R.D., Harris, A.L., et al. (2008) Expression of the Forkhead Transcription Factor FOXP1 Is Associated with That of Estrogen Receptor-Beta in Primary Invasive Breast Carcinomas. Breast Cancer Research and Treatment, 111, 453-459. [Google Scholar] [CrossRef] [PubMed]
[17] Rayoo, M., Yan M., Takano, E.A., Bates, G.J., Brown, P.J., Banham, A.H., et al. (2009) Expression of the Forkhead Box Transcription Factor FOXP1 Is Associated with Oestrogen Receptor Alpha, Oestrogen Receptor Beta and Improved Survival in Familial Breast Cancers. Journal of Clinical Pathology, 62, 896-902. [Google Scholar] [CrossRef] [PubMed]
[18] Sethi, S., Sethi, S. and Bluth, M.H. (2018) Clinical Implication of MicroRNAs in Molecular Pathology: An Update for 2018. Clinics in Laboratory Medicine, 38, 237-251. [Google Scholar] [CrossRef] [PubMed]
[19] Qian, D., Chen, K., Deng, H., Rao, H., Huang, H., Liao, Y., et al. (2015) MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-Cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clinical Cancer Research, 21, 4881-4891. [Google Scholar] [CrossRef] 
[20] Qin, W., Xie, W., He, Q., Sun, T., Meng, C., Yang, K., et al. (2018) MicroRNA-152 Inhibits Ovarian Cancer Cell Proliferation and Migration and May Infer Improved Outcomes in Ovarian Cancer through Targeting FOXP1. Experimental and Therapeutic Medicine, 15, 1672-1679. [Google Scholar] [CrossRef] [PubMed]
[21] Grunewald, T. and Ledermann, J.A. (2017) Targeted Therapies for Ovarian Cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 41, 139-152. [Google Scholar] [CrossRef] [PubMed]
[22] Modugno, F. and Edwards, R.P. (2012) Ovarian Cancer: Prevention, Detection, and Treatment of the Disease and Its Recurrence. Molecular Mechanisms and Personalized Medicine Meeting Report. International Journal of Gynecologic Cancer, 22, S45-S57. [Google Scholar] [CrossRef] 

为你推荐